Skip to Content

Cladribine in MS: A Key to Slowing Aging and Protecting Brain Health

As more effective MS treatments allow patients to live longer, aging-related challenges become more apparent. Dr. Gavin Giovannoni, Professor of Neurology at Queen Mary University of London, UK, explains that aging accelerates cognitive decline and disability in MS due to reduced brain reserve and early senescence. He emphasizes that early treatment with therapies like cladribine can slow brain volume loss and improve outcomes, especially when initiated early in the disease course.

Gavin Giovannoni

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top